Experience of Long Term Treatment and Different Dosage Regimens of Isosorbide 5-Mononitrate

Authors:
  • MMM. Meffert
    M. Meffert

Abstract
The results of 2 clinical studies of controlled-release isosorbide 5-mononitrate (Imdur®) in patients with angina pectoris are presented. In an open study in 106 patients the antianginal efficacy of controlled-release isosorbide 5-mononitrate 60mg once daily was demonstrated by a progressive reduction in the use of short-acting glyceryl trinitrate and in the number of anginal attacks over 6 months. The only significant side effect was headache, which generally disappeared rapidly (after an average of 5 to 6 days). 30 patients were treated in a 1-week single-blind crossover study comparing controlled-release isosorbide 60mg once daily with a conventional formulation of the drug 20mg 3 times daily. Both regimens produced similar antianginal and anti-ischaemic effects when the patients were tested by standard ergometry, and the only significant side effect (transient headache) was equally frequent with both regimens.

This publication has 14 references indexed in Scilit: